CASTILLO LABORDE, CARLA CECILIA
Thumbnail Image
Preferred name
CASTILLO LABORDE, CARLA CECILIA
Main Affiliation
Email
carlacastillo@udd.cl
ORCID
Scopus Author ID
36699176800

Research Output

2022 2022 2021 2021 2020 2020 0.0 0.0 0.2 0.2 0.4 0.4 0.6 0.6 0.8 0.8 1.0 1.0 1.2 1.2 1.4 1.4 1.6 1.6 1.8 1.8 2.0 2.0

Filters

1
3
3
Reset filters

Settings
Now showing 1 - 3 of 3
No Thumbnail Available
Publication

Under five and infant mortality in Chile (1990-2016): Trends, disparities, and causes of death

2020 , AGUILERA SANHUEZA, XIMENA PAZ , Gloria Icaza , DELGADO BECERRA, OROZIMBA IRIS , Loreto Villanueva , APABLAZA SALINAS, MAURICIO IVÁN , CASTILLO LABORDE, CARLA CECILIA , Hajo Zeeb

View
No Thumbnail Available
Publication

Immunization and SARS-CoV-2 Antibody Seroprevalence in a Country with High Vaccination Coverage: Lessons from Chile

2022 , AGUILERA SANHUEZA, XIMENA PAZ , Gloria Icaza , GONZALEZ WIEDMAIER, CLAUDIA MARTA , RUBILAR RAMIREZ, PAOLA , APABLAZA SALINAS, MAURICIO IVÁN , Muriel Ramírez-Santana , PEREZ ACUÑA, CLAUDIA VERONICA , CORTES SALINAS, LINA JIMENA , Loreto Núñez-Franz , Rubén Quezada-Gaete , CASTILLO LABORDE, CARLA CECILIA , Juan Correa , Macarena Said , HORMAZABAL CASTILLO, JUAN PATRICIO , VIAL COX, MARIA CECILIA , VIAL CLARO, PABLO AGUSTIN

Chile is among the most successful nations worldwide in terms of its COVID-19 vaccine rollout. By 31 December 2021, 84.1% of the population was fully vaccinated, and 56.1% received booster doses using different COVID-19 vaccines. In this context, we aimed to estimate the prevalence of anti-SARS-CoV-2 antibodies following the infection and vaccination campaign. Using a three-stage stratified sampling, we performed a population-based cross-sectional serosurvey based on a representative sample of three Chilean cities. Selected participants were blood-sampled on-site and answered a short COVID-19 and vaccination history questionnaire using Wantai SARS-CoV-2 Ab ELISA to determine seroprevalence. We recruited 2198 individuals aged 7–93 between 5 October and 25 November 2021; 2132 individuals received COVID-19 vaccinations (97%), 67 (3.1%) received one dose, 2065 (93.9%) received two doses, and 936 received the booster jab (42.6%). Antibody seroprevalence reached 97.3%, ranging from 40.9% among those not vaccinated to 99.8% in those with booster doses (OR = 674.6, 154.8–2938.5). SARS-CoV-2 antibodies were associated with vaccination, previous COVID-19 diagnosis, age group, and city of residence. In contrast, we found no significant differences in the type of vaccine used, education, nationality, or type of health insurance. We found a seroprevalence close to 100%, primarily due to the successful vaccination program, which strongly emphasizes universal access.

View
No Thumbnail Available
Publication

SARS-CoV-2 Neutralizing Antibodies in Chile after a Vaccination Campaign with Five Different Schemes

2022 , AGUILERA SANHUEZA, XIMENA PAZ , HORMAZABAL CASTILLO, JUAN PATRICIO , VIAL COX, MARIA CECILIA , CORTES SALINAS, LINA JIMENA , GONZALEZ WIEDMAIER, CLAUDIA MARTA , RUBILAR RAMIREZ, PAOLA , APABLAZA SALINAS, MAURICIO IVÁN , Muriel Ramírez-Santana , Gloria Icaza , Loreto Nuñez-Franz , Rubén Quezada-Gate , Macarena Said , PEREZ ACUÑA, CLAUDIA VERONICA , CASTILLO LABORDE, CARLA CECILIA , Carolina Sacristán Ramírez , VIAL CLARO, PABLO AGUSTIN

Using levels of neutralizing antibodies (nAbs), we evaluate the successful Chilean SARS-CoV-2 vaccine campaign, which combines different vaccine technologies and heterologous boosters. From a population-based study performed in November 2021, we randomly selected 120 seropositive individuals, organized into six groups of positive samples (20 subjects each) according to natural infection history and the five most frequent vaccination schemes. We conclude that the booster dose, regardless of vaccine technology or natural infection, and mRNA vaccines significantly improve nAbs response.

View